Chugai Pharmabody Research Pte. Ltd. (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis (Geneo from September 2026) in Singapore, it aims to generate new antibody drugs based on Chugai’s proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are under development.

CPR is seeking a Senior Scientist with deep expertise in cell biology or pharmacology to advance regenerative medicine and cardiovascular/ metabolic (CVM) drug discovery, as well as to help shape novel therapeutic concepts. Reporting to the Research Manager, you will lead multidisciplinary projects from concept through execution, develop and v...